Last updated on January 2020

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO]

Brief description of study

Patients with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized to selinexor or placebo until disease progression.

Clinical Study Identifier: NCT03555422

Find a site near you

Start Over

UZ Leuven

Leuven, Belgium
  Connect »

Arizona Oncology

Tucson, AZ United States
  Connect »

Moffitt Cancer Center

Tampa, FL United States
  Connect »

Northside Hospital

Atlanta, GA United States
  Connect »

Covenant HealthCare

Saginaw, MI United States
  Connect »

AZ Turnhout

Turnhout, Belgium
  Connect »

Stanford University

Palo Alto, CA United States
  Connect »

University of Oklahoma Health

Oklahoma City, OK United States
  Connect »